RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration ("FDA") has denied its most recent application seeking Breakthrough Therapy designation ("BTD") for aviptadil.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.94 USD | +4.63% | +36.24% | -35.43% |
06/05 | NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data | DJ |
06/05 | NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.43% | 29.28M | |
+22.59% | 46.4B | |
-1.57% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+9.75% | 26.01B | |
-19.47% | 19.52B | |
+30.18% | 12.43B | |
0.00% | 12.18B | |
-0.70% | 12.13B |
- Stock Market
- Equities
- BRPA Stock
- News NRx Pharmaceuticals, Inc.
- NRx Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Denied for aviptadil